Researchers exploited for the first time cellular self-recognition process for targeting glioblastoma cells with boron nitride nanotubes (BNNTs), a biocompatible, yet inorganic, nanomaterial.
The team loaded the BNNTs with doxorubicin, a powerful chemotherapy drug, and then functionalized them with glioblastoma cell membranes This targeting approach benefits from the ability of cancer cells to recognize each other due to similarities present on their membrane that make them different from healthy cells.
